Tech Company Financing Transactions
Vensica Medical Funding Round
On 10/28/2024, Vensica Medical received $11 million in investment from Israel Biotech Fund, Laborie Medical Technologies and Merz Pharma.
Transaction Overview
Company Name
Announced On
10/28/2024
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its upcoming Phase 2 clinical trials across the United States and Europe for its treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
6 Hagavish Street
Netanya, 4250706
Israel
Netanya, 4250706
Israel
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We are pioneering breakthrough urology therapeutics designed for localized delivery with Vibe®, a disruptive ultrasound drug delivery technology. Vensica is developing ViXe, a product that combines Xeomin®, a commercial neurotoxin, and Vibe, a breakthrough, needle-free, ultrasound drug delivery device.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Avner Geva
Chief Technical Officer
Avi Eftel
Browse more venture capital transactions:
Prev: 10/28/2024: Reactiv venture capital transaction
Next: 10/28/2024: PebblePad venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs